$1.80
4.26% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
CH0329023102
Symbol
ACIU
Sector
Industry

AC Immune SA Stock price

$1.88
-0.52 21.67% 1M
-1.60 45.98% 6M
-0.82 30.37% YTD
-0.82 30.37% 1Y
-2.59 57.94% 3Y
-5.70 75.20% 5Y
-13.78 87.99% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.09 4.74%
ISIN
CH0329023102
Symbol
ACIU
Sector
Industry

Key metrics

Market capitalization $186.01m
Enterprise Value $9.39m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.13
EV/Sales (TTM) EV/Sales 0.30
P/S ratio (TTM) P/S ratio 5.91
P/B ratio (TTM) P/B ratio 1.52
Revenue growth (TTM) Revenue growth 88.63%
Revenue (TTM) Revenue $31.47m
EBIT (operating result TTM) EBIT $-59.12m
Free Cash Flow (TTM) Free Cash Flow $74.39m
Cash position $182.61m
EPS (TTM) EPS $-0.57
P/E forward negative
P/S forward 6.52
EV/Sales forward 0.33
Short interest 2.84%
Show more

Is AC Immune SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

AC Immune SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a AC Immune SA forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a AC Immune SA forecast:

Buy
100%

Financial data from AC Immune SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
31 31
89% 89%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
21% 21%
47%
- Research and Development Expense 71 71
17% 17%
226%
-57 -57
3% 3%
-180%
- Depreciation and Amortization 2.46 2.46
0% 0%
8%
EBIT (Operating Income) EBIT -59 -59
3% 3%
-188%
Net Profit -57 -57
5% 5%
-182%

In millions USD.

Don't miss a Thing! We will send you all news about AC Immune SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AC Immune SA Stock News

Neutral
GlobeNewsWire
one day ago
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
Neutral
GlobeNewsWire
9 days ago
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diver...
Neutral
GlobeNewsWire
21 days ago
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome ...

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Head office Switzerland
CEO Andrea Pfeifer
Employees 172
Founded 2003
Website www.acimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today